Hypnotic activity of melatonin - PubMed (original) (raw)

Clinical Trial

. 2000 Aug 1;23(5):663-9.

Affiliations

• PMID: 10947034

Clinical Trial

Hypnotic activity of melatonin

B M Stone et al. Sleep. 2000.

Abstract

Objective: To establish the effect of melatonin upon nocturnal and evening sleep.

Methods: Experiment I: The effect of melatonin (0.1, 0.5, 1.0, 5.0, and 10 mg), ingested at 23:30, was studied on nocturnal sleep (23:30-07:30) and core body temperature in 8 healthy volunteers. Performance was measured 8.5 h post-ingestion. On completion of the experiment dim light melatonin onsets (DLMO) were determined. Experiment II: The effect of melatonin (0.5, 1.0, 5.0, and 10 mg), ingested at 18:00, was studied on evening sleep (18:00-24:00) and core body temperature in 6 healthy volunteers. Performance was measured 6.5 h post-ingestion. Each experiment was placebo-controlled and double-blind with a cross-over design with temazepam (20 mg) as an active control.

Results: Experiment I: Melatonin (5 mg) reduced the duration of stage 3 in the first 100 min of sleep. Melatonin (0.1 mg) reduced body temperature 6.5 to 7 h post-ingestion. Temazepam increased stage 2, reduced wakefulness and stage 1, and increased the latency to REM sleep. Temazepam reduced body temperature 4.5 to 6.5 h post-ingestion. There were no changes in performance compared with placebo. DLMO occurred between 20:40 and 23:15. Experiment II: Melatonin (all doses) increased total sleep time (TST), sleep efficiency index (SEI) and stage 2, and reduced wakefulness. Temazepam increased TST, SEI, stage 2 and slow-wave sleep, and reduced wakefulness. There were no changes in body temperature or performance compared with placebo.

Conclusion: Melatonin given at 23:30 has no significant clinical effect on nocturnal sleep in healthy individuals. Hypnotic activity of melatonin when given in the early evening (presumably in the absence of endogenous melatonin) is similar to 20 mg temazepam.

PubMed Disclaimer

Similar articles

• The hypnotic effects of melatonin treatment on diurnal sleep in humans.
  Matsumoto M. Matsumoto M. Psychiatry Clin Neurosci. 1999 Apr;53(2):243-5. doi: 10.1046/j.1440-1819.1999.00480.x. Psychiatry Clin Neurosci. 1999. PMID: 10459700 Clinical Trial.
• Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people.
  Arbon EL, Knurowska M, Dijk DJ. Arbon EL, et al. J Psychopharmacol. 2015 Jul;29(7):764-76. doi: 10.1177/0269881115581963. Epub 2015 Apr 28. J Psychopharmacol. 2015. PMID: 25922426 Clinical Trial.
• Dose effects of temazepam in transient insomnia.
  Roehrs T, Vogel G, Sterling W, Roth T. Roehrs T, et al. Arzneimittelforschung. 1990 Aug;40(8):859-62. Arzneimittelforschung. 1990. PMID: 2242077 Clinical Trial.
• Melatonin as a hypnotic: con.
  van den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D. van den Heuvel CJ, et al. Sleep Med Rev. 2005 Feb;9(1):71-80. doi: 10.1016/j.smrv.2004.07.001. Sleep Med Rev. 2005. PMID: 15649741 Review.
• Chronobiotic protocol and circadian sleep propensity index: new tools for clinical routine and research on melatonin and sleep.
  Kunz D. Kunz D. Pharmacopsychiatry. 2004 Jul;37(4):139-46. doi: 10.1055/s-2004-827167. Pharmacopsychiatry. 2004. PMID: 15467968 Review.

Cited by

• Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial.
  Revell VL, Della Monica C, Mendis J, Hassanin H, Halter RJ, Chaplan SR, Dijk DJ. Revell VL, et al. Neuropsychopharmacology. 2022 Feb;47(3):719-727. doi: 10.1038/s41386-021-01175-3. Epub 2021 Oct 9. Neuropsychopharmacology. 2022. PMID: 34628482 Free PMC article. Clinical Trial.
• Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.
  Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, Montgomery P, Whitehouse WP, Choonara I, Allport T, Edmond A, Appleton R; MENDS Study Group. Gringras P, et al. BMJ. 2012 Nov 5;345:e6664. doi: 10.1136/bmj.e6664. BMJ. 2012. PMID: 23129488 Free PMC article. Clinical Trial.
• Role of the melatonin system in the control of sleep: therapeutic implications.
  Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Pandi-Perumal SR, et al. CNS Drugs. 2007;21(12):995-1018. doi: 10.2165/00023210-200721120-00004. CNS Drugs. 2007. PMID: 18020480 Review.
• Sex Differences in Sleep Architecture After Traumatic Brain Injury: Potential Implications on Short-Term Episodic Memory and Recovery.
  Howell SN, Griesbach GS. Howell SN, et al. Neurotrauma Rep. 2024 Jan 3;5(1):3-12. doi: 10.1089/neur.2023.0093. eCollection 2024. Neurotrauma Rep. 2024. PMID: 38249321 Free PMC article.
• Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans.
  Rajaratnam SM, Middleton B, Stone BM, Arendt J, Dijk DJ. Rajaratnam SM, et al. J Physiol. 2004 Nov 15;561(Pt 1):339-51. doi: 10.1113/jphysiol.2004.073742. Epub 2004 Sep 30. J Physiol. 2004. PMID: 15459246 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.